Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 clinical study for ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease

Trial Profile

A Phase 3 clinical study for ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ketamine (Primary)
  • Indications Dyskinesias; Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors PharmaTher
  • Most Recent Events

    • 29 Mar 2023 According to a PharmaTher media release, company announced an update on the Type C meeting with the US FDA for advancing KETARX towards Phase 3 clinical study as a treatment for levodopa-induced dyskinesia in Parkinson disease, the Company plans to adapt its proposed clinical development program to align with the FDA recommendations and the Company resources towards study evaluations leading into a Phase 3 study and a potential FDA marketing approval via the 505(b)(2) regulatory pathway.
    • 01 Feb 2023 According to PharmaTher media release, the company has submitted its meeting package with the U.S. Food and Drug Administration ("FDA") to discuss with the FDA its plans for a Phase 3 clinical study. The Type C meeting is via written responses and FDA written responses expected in March 20, 2023. The Company has requested guidance from the FDA to obtain Fast Track Designation for KETARX™.
    • 11 Jan 2023 According to PharmaTher media release, type C meeting is granted by FDA for potential phase III clinical study in the treatment of levodopa-induced dyskinesia in Parkinson patients.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top